Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: A placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)
British Journal of Dermatology Dec 02, 2017
de Bruin-Weller M, et al. - An inspection was conducted of the efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS), in adults with atopic dermatitis (AD) with inadequate response to/intolerance of Ciclosporin A (CsA), or for whom CsA was medically inadvisable. The combination of dupilumab+TCS considerably improved the signs and symptoms of AD and quality of life (QOL) in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. Findings did not reveal any new safety signals.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
